Industry Representatives Call For An Increase In Patent Protection

BMI View: Innovation-based pharmaceutical companies require stable, predictable and internationally competitive intellectual property (IP) laws as well as a fast regulatory approval system to ensure their research and development (R&D) projects are commercially viable. However, BMI believes that increasing IP protection alone is not enough to make a particular country globally competitive in attracting R&D investment from multinational drugmakers. The industry is currently facing several challenges to maintain venture capital inflows to fund R&D. We believe that cost-containment measures will accelerate and R&D projects will be increasingly outsourced from lower-cost bases.

To read the full article, please choose one of the following options: